Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

被引：0
|
作者：
Yan, Wenqiang [1 ,2 ,3 ]
Li, Lingna [1 ,2 ]
Fan, Huishou [1 ,2 ]
Xu, Jingyu [1 ,2 ]
Deng, Shuhui [1 ,2 ]
Sui, Weiwei [1 ,2 ]
Xu, Yan [1 ,2 ]
Zou, Dehui [1 ,2 ]
Qiu, Lugui [1 ,2 ]
An, Gang [1 ,2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[3] Inst Hematol & Blood, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158751
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7255 / 7256
页数：2
相关论文
共 50 条
  • [41] Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China
    Sui, Weiwei
    An, Gang
    Deng, Shuhui
    Xu, Yan
    Hao, Mu
    Fu Mingwei
    Wang, Tingyu
    Yi, Shuhua
    Zhao, Yaozhong
    Zou, Dehui
    Li, Zengjun
    Qiu, Lugui
    [J]. BLOOD, 2019, 134
  • [42] From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population
    Delea, Thomas E.
    Ma, Qiufei
    Kroog, Glenn S.
    Ge, Wenzhen
    Moynahan, Aaron
    Anaya, Natalia Sabater
    Lorenc, Karen Rodriguez
    Song, Xue
    [J]. ONCOLOGY AND THERAPY, 2024, 12 (03) : 565 - 583
  • [43] Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
    Zhong, Ling
    Hao, Peng
    Zhang, Qian
    Jiang, Tao
    Li, Huan
    Xiao, Jialing
    Li, Chenglong
    Luo, Lan
    Xie, Chunbao
    Hu, Jiang
    Wang, Liang
    Liu, Yuping
    Shi, Yi
    Zhang, Wei
    Gong, Bo
    [J]. ELIFE, 2022, 11 : 1 - 29
  • [44] The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma
    Galieni, Piero
    Travaglini, Fosco
    Vagnoni, Davide
    Ruggieri, Miriana
    Caraffa, Patrizia
    Bigazzi, Catia
    Falcioni, Sadia
    Picardi, Paola
    Mazzotta, Serena
    Troiani, Emanuela
    Dalsass, Alessia
    Mestichelli, Francesca
    Angelini, Mario
    Camaioni, Elisa
    Maravalle, Denise
    Angelini, Stefano
    Pezzoni, Valerio
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 542 - 550
  • [45] FIRST-LINE THERAPY FOR MULTIPLE MYELOMA (MM): RESULTS FROM THE SECOND INTERIM ANALYSIS OF THE REAL-WORLD, INTERNATIONAL, NON-INTERVENTIONAL EMMOS STUDY
    Mohty, M.
    Terpos, E.
    Mateos, M. V.
    Palumbo, A.
    Lejniece, S.
    Beksac, M.
    Bekadja, M. A.
    Legiec, W.
    Dimopoulos, M.
    Stankovic, S.
    Duran, M. S.
    De Stefano, V.
    Kochkareva, Y.
    Laane, E.
    Berthou, C.
    Salwender, H.
    Masliak, Z.
    Peceliunas, V.
    Willenbacher, W.
    Silva, J.
    Louw, V.
    Nemet, D.
    Borbenyi, Z.
    Abadi, U.
    Pedersen, R. S.
    Cernelc, P.
    Potamianou, A.
    Couturier, C.
    Olie, R.
    Feys, C.
    Thoret-Bauchet, F.
    Boccadoro, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 360 - 361
  • [46] A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform
    D'Agostino, Mattia
    Lahuerta, Juan-Jose
    Wester, Ruth
    Waage, Anders
    Bertsch, Uta
    Zamagni, Elena
    Mateos, Maria-Victoria
    Larocca, Alessandra
    Dall'Olio, Daniele
    van de Donk, Niels W. C. J.
    Cairns, David
    Rocchi, Serena
    Salwender, Hans
    Creixenti, Joan Blade
    van der Holt, Bronno
    Gastone, Castellani
    Ciccone, Giovannino
    Capra, Andrea
    Durig, Jan
    Bringhen, Sara
    Zweegman, Sonja
    Cavo, Michele
    Goldschmidt, Hartmut
    Cook, Gordon
    Hernandez-Rivas, Jesus Maria
    San-Miguel, Jesus F.
    Boccadoro, Mario
    Sonneveld, Pieter
    [J]. BLOOD, 2020, 136
  • [47] The significance of beta-II microglobulin (β2M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI).
    Lin, Gloria
    Hari, Parameswaran
    Chhabra, Saurabh
    Hamadani, Mehdi
    D'Souza, Anita
    Szabo, Aniko
    Dhakal, Binod
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study.
    Tay, Jason
    Chen, Guanmin
    Cowling, Tara
    Shaw, Eileen
    Farris, Megan
    Liu, Fei Fei
    Jimenez-Zepeda, Victor H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] BORTEZOMIB-BASED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-WORLD MEDICAL PRACTICE: FINAL DATA FROM THE INTERNATIONAL, OBSERVATIONAL EVOBS STUDY
    Terpos, E.
    Katodritou, E.
    de la Rubia, J.
    Hungria, V.
    Hulin, C.
    Roussou, M.
    Delforge, M.
    Bries, G.
    Stoppa, A.
    Aagesen, J.
    Sargin, D.
    Belch, A.
    Diels, J.
    Chirita, O.
    Olie, R.
    Robinson, D., Jr.
    Dhawan, R.
    Ganguly, R.
    Potamianou, A.
    van de Velde, H.
    Dimopoulos, M.
    [J]. HAEMATOLOGICA, 2013, 98 : 601 - 601
  • [50] Real-world attrition rates after second-line therapy or later in patients from the flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide
    Dhakal, Binod
    Einsele, Hermann
    Schecter, Jordan
    Deraedt, William
    Lendvai, Nikoletta
    Slaughter, Ana
    Lonardi, Carolina
    Nair, Sandhya
    He, Jianming
    Kharat, Akshay
    Cost, Patricia
    Valluri, Satish
    Fonseca, Rafael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S171 - S171
12345